Amedisys (AMED)
(Delayed Data from NSDQ)
$96.80 USD
-0.91 (-0.93%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $96.80 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$96.80 USD
-0.91 (-0.93%)
Updated Nov 7, 2024 04:00 PM ET
After-Market: $96.80 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value B Growth D Momentum B VGM
Zacks News
Buy These 5 Low Leverage Stocks on Chances of Rate Hike
by Zacks Equity Research
Prudent investors try to avoid companies with large debt loads since they are more vulnerable during economic downturns.
Brush Off Volatility Concerns With These 5 Low-Beta Stocks
by Zacks Equity Research
We create a strategy that singles out less-risky stocks which can generate impressive returns only when certain parameters are considered.
5 Knockout Stocks to Play the World Cup Fever Pitch
by Ritujay Ghosh
Much like any tournament can't be won without putting up a strong fight, markets too go through ups and downs. Amid all the odds, stock winners leave a mark with their performance.
Is Amedisys (AMED) a Great Growth Stock?
by Zacks Equity Research
Amedisys (AMED) is seeing solid earnings estimate revision and has a favorable Zacks rank, making it well positioned for future earnings growth.
QIAGEN (QGEN) Banks on Molecular Diagnostics, Global Growth
by Zacks Equity Research
QIAGEN's (QGEN) progress with the test menu expansion is impressive. Earlier in Q1, the company also secures the Japanese approval for QuantiFERON-TB Gold Plus as an in vitro diagnostic to detect TB.
Buy These 5 Low Leverage Stocks Amid Rising Trade Tensions
by Zacks Equity Research
For a safe investment strategy, understanding the amount of financial leverage that a company bears is crucial. This is because financial leverage multiplies the underlying business risk.
Hologic's New Panther Fusion System Gets Health Canada Nod
by Zacks Equity Research
Hologic's (HOLX) receipt of Health Canada approval for the new Panther Fusion system and Panther Fusion assays, for respiratory virus infections, is expected to boost the top line in the near term.
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Amedisys' (AMED) solid performance in the recently launched Personal Care segment buoys optimism. A favorable demographic trend and strategic acquisitions also bode well for the company.
Medtronic's Expanded IN.PACT Admiral FDA Nod to Aid APV Arm
by Zacks Equity Research
Medtronic's (MDT) receipt of FDA approval for 200mm and 250mm lengths of the IN.PACT Admiral Drug-Coated Balloon (DCB) is expected to boost the top line.
Envision Healthcare's (EVHC) Ratings on Review for Downgrade
by Zacks Equity Research
Moody's Investor Service puts Envision Healthcare's (EVHC) ratings and outlook on review for downgrade.
Zacks.com highlights: G-III Apparel Group, Momo, Weight Watchers International, Amedisys and Urban Outfitters
by Zacks Equity Research
Zacks.com highlights: G-III Apparel Group, Momo, Weight Watchers International, Amedisys and Urban Outfitters
CVS Health's PBM Selling Season Remains Solid, Retail Grows
by Zacks Equity Research
CVS Health (CVS) significantly advances more than halfway through its 2019 renewals. Also, strong year-over-year Retail/LTC comparisons are encouraging.
5 Stocks to Snap Up on Explosive Relative Price Strength
by Nilanjan Choudhury
Want to try an out-of-the-box approach to earn handsome returns? Tap these stocks with explosive relative price strength.
Top Ranked Momentum Stocks to Buy for June 11th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 11th:
Top Ranked Momentum Stocks to Buy for June 8th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 8th:
Here's Why You Should Invest in Genomic Health (GHDX) Now
by Zacks Equity Research
Genomic Health (GHDX) gains ground on promising reimbursement prospects for its Oncotype DX breast cancer test and solid international scenario.
ResMed Reports Positive Results for Bilevel PAP Device Study
by Zacks Equity Research
Positive results from the Bilevel Rescue study are expected to boost the uptake of ResMed's (RMD) bilevel devices.
Why Amedisys (AMED) Stock Might be a Great Pick
by Zacks Equity Research
Amedisys (AMED) is seeing solid earnings estimate revision activity and is a great company from a Zacks Industry Rank perspective.
Amedisys (AMED) Up 17% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Amedisys (AMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Amedisys (AMED) Buys Back 2.4M Shares From KKR, Stock Up
by Zacks Equity Research
Amedisys (AMED) works on its strategy to deploy capital in an accretive manner, maintaining low leverage and substantial borrowing capacity for future investment.
Medtronic's (MDT) CRHF Arm Growth Strong, Rising Costs a Woe
by Zacks Equity Research
The gradually stabilizing Cardiac Rhythm & Heart Failure (CRHF) market increases investor confidence in the Medtronic (MDT) stock.
Buy These 5 Low Leverage Stocks to Secure Your Portfolio
by Zacks Equity Research
The stage is set for the U.S. market to be on an upward trajectory, raising hopes for upswings in the future. Yet investors should calculate a company's leverage before investing in the stock.
Boston Scientific Grows on New Products Amid Recall Issues
by Zacks Equity Research
Boston Scientific's (BSX) 2018 guidance raises optimism for the company's near-term prospects.
Bruker Unveils New Mass-Spectrometry Products, Boosts CALID
by Zacks Equity Research
Bruker's (BRKR) mass-spectrometry business within its CALID group rides high on strong sales performances in recent times.
Abbott Launches Afinion 2 Analyzer Rapid Test in the U.S.
by Zacks Equity Research
Abbott's (ABT) recently-launched Afinion 2 analyzer system is likely to boost top-line contributions from the Diagnostic division.